Sweden's Omnio Secures €2.9 Million for Chronic Wound Therapy

Swedish biotech Omnio has raised €2.9 million to advance its plasminogen-based therapy for hard-to-heal chronic wounds, according to EU-Startups.

The round anchors the company's clinical work on a treatment that targets one of the most persistent problems in wound care: chronic wounds that fail to close through standard treatment. Omnio's approach centers on plasminogen, a protein the body uses in wound healing, and applies it as a therapeutic for patients whose healing process has stalled.

The €2.9 million commitment gives the Swedish company capital to push its plasminogen-based candidate further along the development path. For a clinical-stage biotech, financing at this scale typically funds the mid-stage work that determines whether a therapy can move toward regulatory review and commercialization.

Chronic wounds represent a growing burden for healthcare systems. Wounds that refuse to heal — often tied to diabetes, vascular disease, and aging populations — generate repeated clinic visits, long courses of treatment, and significant cost. Existing options frequently fall short, leaving a gap that companies like Omnio are trying to fill with biology-driven therapies rather than conventional dressings and interventions.

Omnio's choice of plasminogen as a therapeutic platform reflects a broader shift in wound care toward addressing the underlying biological reasons healing stalls, rather than managing symptoms. The company is based in Sweden, whose life sciences sector has produced a steady stream of biotech firms working on protein-based and regenerative medicines.

The funding news was reported by EU-Startups, a European startup publication that tracks early-stage financing across the continent. The exact composition of the round — whether it includes venture funds, existing backers, or new investors — was not disclosed in the report.

For Omnio, the next phase is straightforward: use the €2.9 million to advance the plasminogen-based therapy through its development milestones and generate the evidence needed to attract larger financing or partnership interest. Wound care has drawn attention from bigger pharma and medtech players hunting for differentiated assets, and a successful mid-stage program could position Omnio as an acquisition or licensing target.

The round also signals continued investor appetite for European biotech at the smaller end of the funding spectrum. While mega-rounds dominate headlines, €2.9 million commitments like this one are the capital that keeps early clinical programs alive — and, in indications such as chronic wounds, where patient need is large and treatment options thin, the upside for a therapy that works can be substantial.

Omnio will now focus on proving exactly that, with the therapy's progress through the clinic as the metric that determines whether this round becomes a footnote or the foundation of something larger.